Roxro Pharma’s Phase 3 Intranasal Analgesic Data Receives Excellence Award
ROXRO PHARMA has received an Excellence and Innovation Award for the Phase 3 data of the company’s novel intranasal pain reliever ROX-888, which is in development for the treatment of moderate-to-severe pain. Dr. Neil Singla was the lead author.

Download PDF